Literaturverzeichnis

1. Faustman, D. 1995. Strategies for circumventing transplant rejection: modification of cells, tissues and organs. Trends Biotechnol 13: 100-105.

2. Trucco, M., and G. Stassi. 1996. Transplantation biology. Educating effector T cells. Nature 380: 284-285.

3. Granja, C.B., M. Salazar, and E.J. Yunis. 1996. Population genetics and human leucocyte antigen polymorphism, in Transplantation Biology, N.L. Tilney, T.B. Strom, and L.C. Paul, Editors. Lippincott-Raven, New York. 311-326 pp.

4. VanBuskirk, A.M., D.J. Pidwell, P.W. Adams, and C.G. Orosz. 1997. Transplantation immunology. Jama 278: 1993-1999.

5. Kupiec-Weglinski, J.W., and W.W. Hancock. 1996. Hyperacute and accelerated allograft rejection, in Transplantation Biology, N.L. Tilney, T.B. Strom, and L.C. Paul, Editors. Lippincott-Raven, New York. 541-556 pp.

6. Orloff, M.S., E.M. DeMara, M.L. Coppage, N. Leong, M.A. Fallon, J. Sickel, X.J. Zuo, J. Prehn, and S.C. Jordan. 1995. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation 59: 282-288.

7. Lowry, R.P. 1996. DTH-induced injury, in Transplantation Biology, N.L. Tilney, T.B. Strom, and L.C. Paul, Editors. Lippincott-Raven, New York. 487-502 pp.

8. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.

9. Valitutti, S., S. Muller, M. Dessing, and A. Lanzavecchia. 1996. Signal extinction and T cell repolarization in T helper cell-antigen-presenting cell conjugates. Eur J Immunol 26: 2012-2016.

10. Gould, D.S., and H. Auchincloss, Jr. 1999. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 20: 77-82.

11. Sayegh, M.H., and L.A. Turka. 1998. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338: 1813-1821.

12. Perez, V.L., L. Van Parijs, A. Biuckians, X.X. Zheng, T.B. Strom, and A.K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411-417.

13. Lenschow, D.J., T.L. Walunas, and J.A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258.

14. Rosenberg, A.S., and A. Singer. 1992. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 10: 333-358.

15. Krieger, N.R., D.P. Yin, and C.G. Fathman. 1996. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 184: 2013-2018.

16. Schachter, A.D., L. Vasconcellos, V. Ophascharoensuk, X.X. Zheng, J. Strehlau, and T.B. Strom. 1998. CTL effector mechanisms: diagnostic applications. Transplant Proc 30: 2344-2346.

17. Moon, J.J., and B.H. Nelson. 2001. Phosphatidylinositol 3-kinase potentiates, but does not trigger, T cell proliferation mediated by the IL-2 receptor. J Immunol 167: 2714-2723.

18. Gollob, J.A., C.P. Schnipper, E.A. Murphy, J. Ritz, and D.A. Frank. 1999. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 162: 4472-4481.

19. Hodge, D.L., A. Martinez, J.G. Julias, L.S. Taylor, and H.A. Young. 2002. Regulation of nuclear gamma interferon gene expression by interleukin 12 (IL-12) and IL-2 represents a novel form of posttranscriptional control. Mol Cell Biol 22: 1742-1753.

20. Yu, T.K., E.G. Caudell, C. Smid, and E.A. Grimm. 2000. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol 164: 6244-6251.

21. Malek, T.R., A. Yu, P. Scibelli, M.G. Lichtenheld, and E.K. Codias. 2001. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J Immunol 166: 1675-1683.

22. Steimle, V., C.A. Siegrist, A. Mottet, B. Lisowska-Grospierre, and B. Mach. 1994. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265: 106-109.

23. Wenner, C.A., M.L. Guler, S.E. Macatonia, A. O’Garra, and K.M. Murphy. 1996. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 156: 1442-1447.

24. Bradley, L.M., D.K. Dalton, and M. Croft. 1996. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol 157: 1350-1358.

25. Collart, M.A., D. Belin, J.D. Vassalli, S. de Kossodo, and P. Vassalli. 1986. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med 164: 2113-2118.

26. Ucla, C., P. Roux-Lombard, S. Fey, J.M. Dayer, and B. Mach. 1990. Interferon gamma drastically modifies the regulation of interleukin 1 genes by endotoxin in U937 cells. J Clin Invest 85: 185-191.

27. Nagano, H., R.N. Mitchell, M.K. Taylor, S. Hasegawa, N.L. Tilney, and P. Libby. 1997. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 100: 550-557.

28. Cohen, P. 1982. The role of protein phosphorylation in neural and hormonal control of cellular activity. Nature 296: 613-620.

29. Cohen, P. 1999. The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 3: 459-465.

30. Cohen, P. 2000. The regulation of protein function by multisite phosphorylation—a 25 year update. Trends Biochem Sci 25: 596-601.

31. Campbell, P.M., and P.F. Halloran. 1996. T cell activation, in Transplantation Biology, N.L. Tilney, T.B. Strom, and L.C. Paul, Editors. Lippincott-Raven, New York. 411-434 pp.

32. Schaeffer, H.J., and M.J. Weber. 1999. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444.

33. Han, J., and R.J. Ulevitch. 1999. Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1: E39-40.

34. Davis, R.J. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.

35. Chang, L., and M. Karin. 2001. Mammalian MAP kinase signalling cascades. Nature 410: 37-40.

36. Whitehurst, C.E., and T.D. Geppert. 1996. MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. J Immunol 156: 1020-1029.

37. Dong, C., D.D. Yang, M. Wysk, A.J. Whitmarsh, R.J. Davis, and R.A. Flavell. 1998. Defective T cell differentiation in the absence of Jnk1. Science 282: 2092-2095.

38. Weiss, L., A.J. Whitmarsh, D.D. Yang, M. Rincon, R.J. Davis, and R.A. Flavell. 2000. Regulation of c-Jun NH(2)-terminal kinase (Jnk) gene expression during T cell activation. J Exp Med 191: 139-146.

39. Rivas, F.V., S. O'Herrin, and T.F. Gajewski. 2001. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol 167: 3123-3128.

40. Rincon, M., H. Enslen, J. Raingeaud, M. Recht, T. Zapton, M.S. Su, L.A. Penix, R.J. Davis, and R.A. Flavell. 1998. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. Embo J 17: 2817-2829.

41. Bauer, B., N. Krumbock, N. Ghaffari-Tabrizi, S. Kampfer, A. Villunger, M. Wilda, H. Hameister, G. Utermann, M. Leitges, F. Uberall, and G. Baier. 2000. T cell expressed PKCtheta demonstrates cell-type selective function. Eur J Immunol 30: 3645-3654.

42. Arendt, C.W., B. Albrecht, T.J. Soos, and D.R. Littman. 2002. Protein kinase C-theta;: signaling from the center of the T-cell synapse. Curr Opin Immunol 14: 323-330.

43. Gilmour, K.C., and N.C. Reich. 1994. Receptor to nucleus signaling by prolactin and interleukin 2 via activation of latent DNA-binding factors. Proc Natl Acad Sci U S A 91: 6850-6854.

44. Frank, D.A., M.J. Robertson, A. Bonni, J. Ritz, and M.E. Greenberg. 1995. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A 92: 7779-7783.

45. Ravichandran, K.S., and S.J. Burakoff. 1994. The adapter protein Shc interacts with the interleukin-2 (IL-2) receptor upon IL-2 stimulation. J Biol Chem 269: 1599-1602.

46. Nourse, J., E. Firpo, W.M. Flanagan, S. Coats, K. Polyak, M.H. Lee, J. Massague, G.R. Crabtree, and J.M. Roberts. 1994. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573.

47. Witzke, O., J.A. Barbara, and K.J. Wood. 1999. Induction of tolerance to alloantigen. Rev Immunogenet 1: 374-386.

48. Wekerle, T., M.H. Sayegh, J. Hill, Y. Zhao, A. Chandraker, K.G. Swenson, G. Zhao, and M. Sykes. 1998. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 187: 2037-2044.

49. Wekerle, T., M.H. Sayegh, A. Chandraker, K.G. Swenson, Y. Zhao, and M. Sykes. 1999. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc 31: 680.

50. Gudmundsdottir, H., and L.A. Turka. 2000. Transplantation tolerance: mechanisms and strategies? Semin Nephrol 20: 209-216.

51. Knechtle, S.J., M.M. Hamawy, H. Hu, J.H. Fechner, Jr., and C.S. Cho. 2001. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 183: 205-213.

52. Hale, G., and H. Waldmann. 1994. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 13: 597-611.

53. Novitzky, N., V. Thomas, G. Hale, and H. Waldmann. 1999. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Transplantation 67: 620-626.

54. Shevach, E.M., R.S. McHugh, C.A. Piccirillo, and A.M. Thornton. 2001. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182: 58-67.

55. Thornton, A.M., and E.M. Shevach. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296.

56. Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu, and S. Sakaguchi. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980.

57. Qin, S., S.P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann. 1993. "Infectious" transplantation tolerance. Science 259: 974-977.

58. Onodera, K., A. Chandraker, H.D. Volk, M. Lehmann, S. Korom, T.H. Stadlbauer, K. Kato, S. Kasai, M.H. Sayegh, and J.W. Kupiec-Weglinski. 1998. Role of regulatory T cells in the "infectious" tolerance pathway in transplant recipients. Transplant Proc 30: 13-15.

59. Cobbold, S., and H. Waldmann. 1998. Infectious tolerance. Curr Opin Immunol 10: 518-524.

60. Allen, J.E., and R.M. Maizels. 1997. Th1-Th2: reliable paradigm or dangerous dogma? Immunol Today 18: 387-392.

61. Chen, N., Q. Gao, and E.H. Field. 1996. Prevention of Th1 response is critical for tolerance. Transplantation 61: 1076-1083.

62. Onodera, K., W.W. Hancock, E. Graser, M. Lehmann, M.H. Sayegh, T.B. Strom, H.D. Volk, and J.W. Kupiec-Weglinski. 1997. Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol 158: 1572-1581.

63. Maeda, H., M. Takata, S. Takahashi, S. Ogoshi, and S. Fujimoto. 1994. Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse. Int Immunol 6: 855-862.

64. Sayegh, M.H., E. Akalin, W.W. Hancock, M.E. Russell, C.B. Carpenter, P.S. Linsley, and L.A. Turka. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 181: 1869-1874.

65. Jenkins, M.K., C.A. Chen, G. Jung, D.L. Mueller, and R.H. Schwartz. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 144: 16-22.

66. Schwartz, R.H. 1997. T cell clonal anergy. Curr Opin Immunol 9: 351-357.

67. Alam, S.M., P.J. Travers, J.L. Wung, W. Nasholds, S. Redpath, S.C. Jameson, and N.R. Gascoigne. 1996. T-cell-receptor affinity and thymocyte positive selection. Nature 381: 616-620.

68. Jenkins, M.K. 1992. The role of cell division in the induction of clonal anergy. Immunol Today 13: 69-73.

69. Powell, J.D., D. Bruniquel, and R.H. Schwartz. 2001. TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of p27(Kip1). Eur J Immunol 31: 3737-3746.

70. Wekerle, T., J. Kurtz, H. Ito, J.V. Ronquillo, V. Dong, G. Zhao, J. Shaffer, M.H. Sayegh, and M. Sykes. 2000. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6: 464-469.

71. Benjamin, R.J., and H. Waldmann. 1986. Induction of tolerance by monoclonal antibody therapy. Nature 320: 449-451.

72. Gutstein, N.L., W.E. Seaman, J.H. Scott, and D. Wofsy. 1986. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol 137: 1127-1132.

73. Qin, S., S. Cobbold, H. Tighe, R. Benjamin, and H. Waldmann. 1987. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 17: 1159-1165.

74. Qin, S.X., M. Wise, S.P. Cobbold, L. Leong, Y.C. Kong, J.R. Parnes, and H. Waldmann. 1990. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol 20: 2737-2745.

75. Volk, H.D., A. Siegling, C. Platzer, J. Brock, F. Emmrich, and M. Lehmann. 1994. Tolerance induction by anti-CD4 MAb treatment in a rat kidney transplantation model. Transplant Proc 26: 3155-3156.

76. Motoyama, K., T. Arima, M. Lehmann, and M.W. Flye. 1997. Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (OX-38) with donor antigen administration. Surgery 122: 213-219; discussion 219-220.

77. Lehmann, M., B. Kuttler, A. Siegling, A. Gordalla, H. Riedel, J. Lacha, H.J. Hahn, J. Brock, and H.D. Volk. 1993. Characterization of the anti-CD4-induced permanent acceptance of rat renal allografts. Transplant Proc 25: 2859-2860.

78. Chong, A.S., L. Ma, D. Yin, J. Shen, L. Blinder, X. XiuLong, J. Williams, G. Byrne, L. Diamond, and J. Logan. 2000. Nondepleting anti-CD4 but not anti-CD8 antibody induces long-term survival of xenogeneic and allogeneic hearts in alpha1, 3-galactosyl-transferase knock-out mice. Transplant Proc 32: 1005.

79. Guo, Z., T. Wu, N. Kirchhof, D. Mital, J.W. Williams, M. Azuma, D.E. Sutherland, and B.J. Hering. 2001. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation 71: 1656-1665.

80. Perico, N., S. Amuchastegui, M. Bontempelli, and G. Remuzzi. 1996. CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. Transplantation 61: 1320-1322.

81. Kurlberg, G., E. Haglind, K. Schon, H. Tornqvist, and N. Lycke. 2000. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation. Scand J Immunol 51: 224-230.

82. Pearson, T.C., D.Z. Alexander, K.J. Winn, P.S. Linsley, R.P. Lowry, and C.P. Larsen. 1994. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57: 1701-1706.

83. Graser, E., K. Risch, P.S. Linsley, W.W. Hancock, A. Muller, J. Brock, P. Reinke, J.W. Kupiec-Weglinski, H.D. Volk, and M. Lehmann. 1997. Synergism of CTLA4-IG and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model. Transplant Proc 29: 1307-1309.

84. Najafian, N., and M.H. Sayegh. 2000. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs 9: 2147-2157.

85. Li, Y., X.C. Li, X.X. Zheng, A.D. Wells, L.A. Turka, and T.B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5: 1298-1302.

86. Kirk, A.D., L.C. Burkly, D.S. Batty, R.E. Baumgartner, J.D. Berning, K. Buchanan, J.H. Fechner, Jr., R.L. Germond, R.L. Kampen, N.B. Patterson, S.J. Swanson, D.K. Tadaki, C.N. TenHoor, L. White, S.J. Knechtle, and D.M. Harlan. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5: 686-693.

87. Elster, E.A., H. Xu, D.K. Tadaki, S. Montgomery, L.C. Burkly, J.D. Berning, R.E. Baumgartner, F. Cruzata, R. Marx, D.M. Harlan, and A.D. Kirk. 2001. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 72: 1473-1478.

88. Yamada, and M.H. Sayegh. 2002. The CD154-CD40 costimulatory pathway in transplantation. Transplantation 73: S36-39.

89. Fehervari, Z., A. Cooke, S. Brett, and J. Turner. 2002. Perturbation of naive TCR transgenic T cell functional responses and upstream activation events by anti-CD4 monoclonal antibodies. Eur J Immunol 32: 333-340.

90. Harding, S., P. Lipp, and D.R. Alexander. 2002. A therapeutic CD4 monoclonal antibody inhibits TCR-zeta chain phosphorylation, zeta-associated protein of 70-kDa Tyr319 phosphorylation, and TCR internalization in primary human T cells. J Immunol 169: 230-238.

91. Madrenas, J., R.H. Schwartz, and R.N. Germain. 1996. Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc Natl Acad Sci U S A 93: 9736-9741.

92. Williams, T.M., D. Moolten, J. Burlein, J. Romano, R. Bhaerman, A. Godillot, M. Mellon, F.J. Rauscher, 3rd, and J.A. Kant. 1991. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science 254: 1791-1794.

93. Kitayama, H., Y. Sugimoto, T. Matsuzaki, Y. Ikawa, and M. Noda. 1989. A ras-related gene with transformation suppressor activity. Cell 56: 77-84.

94. Migita, K., K. Eguchi, Y. Kawabe, T. Tsukada, Y. Ichinose, S. Nagataki, and A. Ochi. 1995. Defective TCR-mediated signaling in anergic T cells. J Immunol 155: 5083-5087.

95. Sloan-Lancaster, J., A.S. Shaw, J.B. Rothbard, and P.M. Allen. 1994. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 79: 913-922.

96. Li, W., C.D. Whaley, A. Mondino, and D.L. Mueller. 1996. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271: 1272-1276.

97. Fields, P.E., T.F. Gajewski, and F.W. Fitch. 1996. Blocked Ras activation in anergic CD4+ T cells. Science 271: 1276-1278.

98. Kang, S.M., B. Beverly, A.C. Tran, K. Brorson, R.H. Schwartz, and M.J. Lenardo. 1992. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 257: 1134-1138.

99. Mondino, A., C.D. Whaley, D.R. DeSilva, W. Li, M.K. Jenkins, and D.L. Mueller. 1996. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J Immunol 157: 2048-2057.

100. Boussiotis, V.A., G.J. Freeman, P.A. Taylor, A. Berezovskaya, I. Grass, B.R. Blazar, and L.M. Nadler. 2000. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6: 290-297.

101. Tamma, S.M., N. Chirmule, T.W. McCloskey, N. Oyaizu, V.S. Kalyanaraman, and S. Pahwa. 1997. Signals transduced through the CD4 molecule interfere with TCR/CD3-mediated ras activation leading to T cell anergy/apoptosis. Clin Immunol Immunopathol 85: 195-201.

102. Tamma, S.M., N. Chirmule, H. Yagura, N. Oyaizu, V. Kalyanaraman, and S. Pahwa. 1997. CD4 cross-linking (CD4XL) induces RAS activation and tumor necrosis factor-alpha secretion in CD4+ T cells. Blood 90: 1588-1593.

103. Chirmule, N., A. Avots, S.M. LakshmiTamma, S. Pahwa, and E. Serfling. 1999. CD4-mediated signals induce T cell dysfunction in vivo. J Immunol 163: 644-649.

104. Lehmann, M., E. Graser, K. Risch, W.W. Hancock, A. Muller, B. Kuttler, H.J. Hahn, J.W. Kupiec-Weglinski, J. Brock, and H.D. Volk. 1997. Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells. Transplantation 64: 1181-1187.

105. Lehmann, M., K. Risch, H. Nizze, G. Brandenburg, T. Ritter, J. Brock, and H.D. Volk. 1999. Abolition of anti-CD4-induced allotransplantation tolerance by exogenous IL-2. Transplant Proc 31: 1220-1221.

106. Scully, R., S. Qin, S. Cobbold, and H. Waldmann. 1994. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur J Immunol 24: 2383-2392.

107. Sawitzki, B., M. Lehmann, K. Vogt, K. Risch, J. Brock, J.W. Kupiec-Weglinski, and H.D. Volk. 2002. Bag-1 up-regulation in anti-CD4 mAb treated allo-activated T cells confers resistance to apoptosis. Eur J Immunol 32: 800-809.

108. Sawitzki, B., M. Lehmann, K. Vogt, M. Seifert, K. Risch, J. Brock, J.W. Kupiec-Weglinski, and H.D. Volk. 2002. Bag-1 up-regulation in anti-CD4 mAb-treated allo-activated T cell confers resistance to activation-induced cell death (AICD). Transpl Immunol 9: 83-91.

109. Beissinger, M., and J. Buchner. 1998. How chaperones fold proteins. Biol Chem 379: 245-259.

110. Pratt, W.B., and D.O. Toft. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18: 306-360.

111. Johnson, J.L., T.G. Beito, C.J. Krco, and D.O. Toft. 1994. Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes. Mol Cell Biol 14: 1956-1963.

112. Hutchison, K.A., L.F. Stancato, J.K. Owens-Grillo, J.L. Johnson, P. Krishna, D.O. Toft, and W.B. Pratt. 1995. The 23-kDa acidic protein in reticulocyte lysate is the weakly bound component of the hsp foldosome that is required for assembly of the glucocorticoid receptor into a functional heterocomplex with hsp90. J Biol Chem 270: 18841-18847.

113. Dittmar, K.D., D.R. Demady, L.F. Stancato, P. Krishna, and W.B. Pratt. 1997. Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70. J Biol Chem 272: 21213-21220.

114. Freeman, B.C., S.J. Felts, D.O. Toft, and K.R. Yamamoto. 2000. The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies. Genes Dev 14: 422-434.

115. Kosano, H., B. Stensgard, M.C. Charlesworth, N. McMahon, and D. Toft. 1998. The assembly of progesterone receptor-hsp90 complexes using purified proteins. J Biol Chem 273: 32973-32979.

116. Sullivan, W., B. Stensgard, G. Caucutt, B. Bartha, N. McMahon, E.S. Alnemri, G. Litwack, and D. Toft. 1997. Nucleotides and two functional states of hsp90. J Biol Chem 272: 8007-8012.

117. Freeman, B.C., D.O. Toft, and R.I. Morimoto. 1996. Molecular chaperone machines: chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23. Science 274: 1718-1720.

118. Bose, S., T. Weikl, H. Bugl, and J. Buchner. 1996. Chaperone function of Hsp90-associated proteins [see comments]. Science 274: 1715-1717.

119. Fang, Y., A.E. Fliss, J. Rao, and A.J. Caplan. 1998. SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins. Mol Cell Biol 18: 3727-3734.

120. Bohen, S.P. 1998. Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins. Mol Cell Biol 18: 3330-3339.

121. Knoblauch, R., and M.J. Garabedian. 1999. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol Cell Biol 19: 3748-3759.

122. McLaughlin, S.H., H.W. Smith, and S.E. Jackson. 2002. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol 315: 787-798.

123. Freeman, B.C., and K.R. Yamamoto. 2002. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296: 2232-2235.

124. Forsythe, H.L., J.L. Jarvis, J.W. Turner, L.W. Elmore, and S.E. Holt. 2001. Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J Biol Chem 276: 15571-15574.

125. Akalin, A., L.W. Elmore, H.L. Forsythe, B.A. Amaker, E.D. McCollum, P.S. Nelson, J.L. Ware, and S.E. Holt. 2001. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res 61: 4791-4796.

126. Weng, N., B.L. Levine, C.H. June, and R.J. Hodes. 1997. Regulation of telomerase RNA template expression in human T lymphocyte development and activation. J Immunol 158: 3215-3220.

127. Pratt, W.B. 1997. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 37: 297-326.

128. Pratt, W.B. 1998. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 217: 420-434.

129. Hartson, S.D., D.J. Barrett, P. Burn, and R.L. Matts. 1996. Hsp90-mediated folding of the lymphoid cell kinase p56lck. Biochemistry 35: 13451-13459.

130. Schulte, T.W., M.V. Blagosklonny, C. Ingui, and L. Neckers. 1995. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270: 24585-24588.

131. Schulte, T.W., M.V. Blagosklonny, L. Romanova, J.F. Mushinski, B.P. Monia, J.F. Johnston, P. Nguyen, J. Trepel, and L.M. Neckers. 1996. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf- 1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16: 5839-5845.

132. Helmbrecht, K., E. Zeise, and L. Rensing. 2000. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 33: 341-365.

133. Donze, O., T. Abbas-Terki, and D. Picard. 2001. The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. Embo J 20: 3771-3780.

134. Xu, Z., J.K. Pal, V. Thulasiraman, H.P. Hahn, J.J. Chen, and R.L. Matts. 1997. The role of the 90-kDa heat-shock protein and its associated cohorts in stabilizing the heme-regulated eIF-2alpha kinase in reticulocyte lysates during heat stress. Eur J Biochem 246: 461-470.

135. Fujita, N., S. Sato, A. Ishida, and T. Tsuruo. 2002. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 277: 10346-10353.

136. Sato, S., N. Fujita, and T. Tsuruo. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97: 10832-10837.

137. Pelech, S.L., and D.L. Charest. 1995. MAP kinase-dependent pathways in cell cycle control. Prog Cell Cycle Res 1: 33-52.

138. Wartmann, M., and R.J. Davis. 1994. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J Biol Chem 269: 6695-6701.

139. Schulte, T.W., W.G. An, and L.M. Neckers. 1997. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239: 655-659.

140. Stancato, L.F., A.M. Silverstein, J.K. Owens-Grillo, Y.H. Chow, R. Jove, and W.B. Pratt. 1997. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 272: 4013-4020.

141. Scheibel, T., T. Weikl, and J. Buchner. 1998. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc Natl Acad Sci U S A 95: 1495-1499.

142. Schnaider, T., J. Somogyi, P. Csermely, and M. Szamel. 1998. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes. Life Sci 63: 949-954.

143. Yorgin, P.D., S.D. Hartson, A.M. Fellah, B.T. Scroggins, W. Huang, E. Katsanis, J.M. Couchman, R.L. Matts, and L. Whitesell. 2000. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. J Immunol 164: 2915-2923.

144. Schnaider, T., J. Somogyi, P. Csermely, and M. Szamel. 2000. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation. Cell Stress Chaperones 5: 52-61.

145. Holt, S.E., D.L. Aisner, J. Baur, V.M. Tesmer, M. Dy, M. Ouellette, J.B. Trager, G.B. Morin, D.O. Toft, J.W. Shay, W.E. Wright, and M.A. White. 1999. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 13: 817-826.

146. Morgan, D.O. 1995. Principles of CDK regulation. Nature 374: 131-134.

147. Pines, J. 1995. Cell cycle. Confirmational change. Nature 376: 294-295.

148. Stepanova, L., X. Leng, S.B. Parker, and J.W. Harper. 1996. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 10: 1491-1502.

149. Aligue, R., H. Akhavan-Niak, and P. Russell. 1994. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. Embo J 13: 6099-6106.

150. Munoz, M.J., and J. Jimenez. 1999. Genetic interactions between Hsp90 and the Cdc2 mitotic machinery in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet 261: 242-250.

151. Blagosklonny, M.V., J. Toretsky, S. Bohen, and L. Neckers. 1996. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 93: 8379-8383.

152. Whitesell, L., P.D. Sutphin, E.J. Pulcini, J.D. Martinez, and P.H. Cook. 1998. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18: 1517-1524.

153. Firpo, E.J., A. Koff, M.J. Solomon, and J.M. Roberts. 1994. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 14: 4889-4901.

154. Kovalev, G.I., D.S. Franklin, V.M. Coffield, Y. Xiong, and L. Su. 2001. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol 167: 3285-3292.

155. Goff, S.P. 1992. Genetics of retroviral integration. Annu Rev Genet 26: 527-544.

156. Montagne, J., M.J. Stewart, H. Stocker, E. Hafen, S.C. Kozma, and G. Thomas. 1999. Drosophila S6 kinase: a regulator of cell size. Science 285: 2126-2129.

157. Brennan, P., J.W. Babbage, G. Thomas, and D. Cantrell. 1999. p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Mol Cell Biol 19: 4729-4738.

158. Lafont, V., E. Astoul, A. Laurence, J. Liautard, and D. Cantrell. 2000. The T cell antigen receptor activates phosphatidylinositol 3-kinase-regulated serine kinases protein kinase B and ribosomal S6 kinase 1. FEBS Lett 486: 38-42.

159. Ferris, D.K., A. Harel-Bellan, R.I. Morimoto, W.J. Welch, and W.L. Farrar. 1988. Mitogen and lymphokine stimulation of heat shock proteins in T lymphocytes. Proc Natl Acad Sci U S A 85: 3850-3854.

160. Faassen, A.E., J.J. O'Leary, K.J. Rodysill, N. Bergh, and H.M. Hallgren. 1989. Diminished heat-shock protein synthesis following mitogen stimulation of lymphocytes from aged donors. Exp Cell Res 183: 326-334.

161. Wu, B.J., and R.I. Morimoto. 1985. Transcription of the human hsp70 gene is induced by serum stimulation. Proc Natl Acad Sci U S A 82: 6070-6074.

162. Hensold, J.O., and D.E. Housman. 1988. Decreased expression of the stress protein HSP70 is an early event in murine erythroleukemic cell differentiation. Mol Cell Biol 8: 2219-2223.

163. Helmbrecht, K., and L. Rensing. 1999. Different constitutive heat shock protein 70 expression during proliferation and differentiation of rat C6 glioma cells. Neurochem Res 24: 1293-1299.

164. Hansen, L.K., J.P. Houchins, and J.J. O'Leary. 1991. Differential regulation of HSC70, HSP70, HSP90 alpha, and HSP90 beta mRNA expression by mitogen activation and heat shock in human lymphocytes. Exp Cell Res 192: 587-596.

165. Pieper, M., H.D. Rupprecht, K.M. Bruch, E. De Heer, and H.O. Schocklmann. 2000. Requirement of heat shock protein 90 in mesangial cell mitogenesis. Kidney Int 58: 2377-2389.

166. Becker, J., and E.A. Craig. 1994. Heat-shock proteins as molecular chaperones. Eur J Biochem 219: 11-23.

167. Hartl, F.U. 1996. Molecular chaperones in cellular protein folding. Nature 381: 571-579.

168. Sullivan, W.P., B.A. Owen, and D.O. Toft. 2002. The influence of ATP and p23 on the conformation of hsp90. J Biol Chem 24: 24.

169. Valitutti, S., and A. Lanzavecchia. 1997. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol Today 18: 299-304.

170. Hussain, S.F., C.F. Anderson, and D.L. Farber. 2002. Differential SLP-76 expression and TCR-mediated signaling in effector and memory CD4 T cells. J Immunol 168: 1557-1565.

171. Richter, A., M. Lohning, and A. Radbruch. 1999. Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression. J Exp Med 190: 1439-1450.

172. Gett, A.V., and P.D. Hodgkin. 1998. Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. Proc Natl Acad Sci U S A 95: 9488-9493.

173. Jerome, V., C. Vourc'h, E.E. Baulieu, and M.G. Catelli. 1993. Cell cycle regulation of the chicken hsp90 alpha expression. Exp Cell Res 205: 44-51.

174. Namen, A.E., S. Lupton, K. Hjerrild, J. Wignall, D.Y. Mochizuki, A. Schmierer, B. Mosley, C.J. March, D. Urdal, and S. Gillis. 1988. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333: 571-573.

175. Goodwin, R.G., D. Friend, S.F. Ziegler, R. Jerzy, B.A. Falk, S. Gimpel, D. Cosman, S.K. Dower, C.J. March, A.E. Namen, and et al. 1990. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60: 941-951.

176. Van Snick, J., A. Goethals, J.C. Renauld, E. Van Roost, C. Uyttenhove, M.R. Rubira, R.L. Moritz, and R.J. Simpson. 1989. Cloning and characterization of a cDNA for a new mouse T cell growth factor (P40). J Exp Med 169: 363-368.

177. Paul, W.E. 1991. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77: 1859-1870.

178. Grabstein, K.H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M.A. Schoenborn, M. Ahdieh, and et al. 1994. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264: 965-968.

179. Burton, J.D., R.N. Bamford, C. Peters, A.J. Grant, G. Kurys, C.K. Goldman, J. Brennan, E. Roessler, and T.A. Waldmann. 1994. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 91: 4935-4939.

180. Tagaya, Y., R.N. Bamford, A.P. DeFilippis, and T.A. Waldmann. 1996. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 4: 329-336.

181. Giri, J.G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L.S. Park, D. Cosman, and D. Anderson. 1994. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. Embo J 13: 2822-2830.

182. Bamford, R.N., A.J. Grant, J.D. Burton, C. Peters, G. Kurys, C.K. Goldman, J. Brennan, E. Roessler, and T.A. Waldmann. 1994. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 91: 4940-4944.

183. Waldmann, T.A., S. Dubois, and Y. Tagaya. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14: 105-110.

184. Lodolce, J.P., D.L. Boone, S. Chai, R.E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676.

185. Nakamura, Y., S.M. Russell, S.A. Mess, M. Friedmann, M. Erdos, C. Francois, Y. Jacques, S. Adelstein, and W.J. Leonard. 1994. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 369: 330-333.

186. Nelson, B.H., J.D. Lord, and P.D. Greenberg. 1994. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 369: 333-336.

187. Anderson, D.M., S. Kumaki, M. Ahdieh, J. Bertles, M. Tometsko, A. Loomis, J. Giri, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, and et al. 1995. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 270: 29862-29869.

188. Giri, J.G., D.M. Anderson, S. Kumaki, L.S. Park, K.H. Grabstein, and D. Cosman. 1995. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 57: 763-766.

189. Lin, J.X., and W.J. Leonard. 1997. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 8: 313-332.

190. Imada, K., and W.J. Leonard. 2000. The Jak-STAT pathway. Mol Immunol 37: 1-11.

191. Bulanova, E., V. Budagian, T. Pohl, H. Krause, H. Durkop, R. Paus, and S. Bulfone-Paus. 2001. The IL-15R alpha chain signals through association with Syk in human B cells. J Immunol 167: 6292-6302.

192. Razi-Wolf, Z., G.A. Hollander, and H. Reiser. 1996. Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules. Proc Natl Acad Sci U S A 93: 2903-2908.

193. Boulougouris, G., J.D. McLeod, Y.I. Patel, C.N. Ellwood, L.S. Walker, and D.M. Sansom. 1999. IL-2-independent activation and proliferation in human T cells induced by CD28. J Immunol 163: 1809-1816.

194. Pardee, A.B. 1989. G1 events and regulation of cell proliferation. Science 246: 603-608.

195. Meyuhas, O. 2000. Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 267: 6321-6330.

196. Hidalgo, M., and E.K. Rowinsky. 2000. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686.

197. Perdew, G.H., H. Wiegand, J.P. Vanden Heuvel, C. Mitchell, and S.S. Singh. 1997. A 50 kilodalton protein associated with raf and pp60(v-src) protein kinases is a mammalian homolog of the cell cycle control protein cdc37. Biochemistry 36: 3600-3607.

198. Peter, M. 1997. The regulation of cyclin-dependent kinase inhibitors (CKIs). Prog Cell Cycle Res 3: 99-108.

199. Munoz, M.J., E.R. Bejarano, R.R. Daga, and J. Jimenez. 1999. The identification of Wos2, a p23 homologue that interacts with Wee1 and Cdc2 in the mitotic control of fission yeasts. Genetics 153: 1561-1572.

200. Nair, S.C., E.J. Toran, R.A. Rimerman, S. Hjermstad, T.E. Smithgall, and D.F. Smith. 1996. A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor. Cell Stress Chaperones 1: 237-250.

201. Galea-Lauri, J., D.S. Latchman, and D.R. Katz. 1996. The role of the 90-kDa heat shock protein in cell cycle control and differentiation of the monoblastoid cell line U937. Exp Cell Res 226: 243-254.

202. Caplen, N.J. 2002. A new approach to the inhibition of gene expression. Trends Biotechnol 20: 49-51.

203. Portoles, P., G. de Ojeda, G. Criado, E. Fernandez-Centeno, and J.M. Rojo. 1999. Antibody-induced CD3-CD4 coligation inhibits TCR/CD3 activation in the absence of costimulatory signals in normal mouse CD4(+) T lymphocytes. Cell Immunol 195: 96-109.

204. Stumbles, P., and D. Mason. 1995. Activation of CD4+ T cells in the presence of a nondepleting monoclonal antibody to CD4 induces a Th2-type response in vitro. J Exp Med 182: 5-13.

205. Niedbala, W., X. Wei, and F.Y. Liew. 2002. IL-15 induces type 1 and type 2 CD4+ and CD8+ T cells proliferation but is unable to drive cytokine production in the absence of TCR activation or IL-12 / IL-4 stimulation in vitro. Eur J Immunol 32: 341-347.

206. Zhang, S., and M.H. Kaplan. 2000. The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression.PG - 1374-80. J Immunol 165: 1374-1380.

207. Morley, S.J. 1997. Signalling through either the p38 or ERK mitogen-activated protein (MAP) kinase pathway is obligatory for phorbol ester and T cell receptor complex (TCR-CD3)-stimulated phosphorylation of initiation factor (eIF) 4E in Jurkat T cells. FEBS Lett 418: 327-332.

208. Wang, X., A. Flynn, A.J. Waskiewicz, B.L. Webb, R.G. Vries, I.A. Baines, J.A. Cooper, and C.G. Proud. 1998. The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 273: 9373-9377.

209. Miyamoto, S., S.R. Kimball, and B. Safer. 2000. Signal transduction pathways that contribute to increased protein synthesis during T-cell activation. Biochim Biophys Acta 1494: 28-42.

210. Ward, S.G., and D.A. Cantrell. 2001. Phosphoinositide 3-kinases in T lymphocyte activation. Curr Opin Immunol 13: 332-338.

211. Sasaki, T., J. Irie-Sasaki, R.G. Jones, A.J. Oliveira-dos-Santos, W.L. Stanford, B. Bolon, A. Wakeham, A. Itie, D. Bouchard, I. Kozieradzki, N. Joza, T.W. Mak, P.S. Ohashi, A. Suzuki, and J.M. Penninger. 2000. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration.PG - 1040-6. Science 287: 1040-1046.

212. Edinger, A.L., and C.B. Thompson. 2002. Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient Uptake.PG - 2276-88. Mol Biol Cell 13: 2276-2288.

213. Shioi, T., J.R. McMullen, P.M. Kang, P.S. Douglas, T. Obata, T.F. Franke, L.C. Cantley, and S. Izumo. 2002. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22: 2799-2809.

214. Jefferies, H.B., S. Fumagalli, P.B. Dennis, C. Reinhard, R.B. Pearson, and G. Thomas. 1997. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. Embo J 16: 3693-3704.

215. Jefferies, H.B., C. Reinhard, S.C. Kozma, and G. Thomas. 1994. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family.PG - 4441-5. Proc Natl Acad Sci U S A 91: 4441-4445.

216. Pedersen, S., J.E. Celis, J. Nielsen, J. Christiansen, and F.C. Nielsen. 1997. Distinct repression of translation by wortmannin and rapamycin. Eur J Biochem 247: 449-456.

217. Wang, L., X. Wang, and C.G. Proud. 2000. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps.PG - H1056-68. Am J Physiol Heart Circ Physiol 278: H1056-1068.

218. Dilling, M.B., G.S. Germain, L. Dudkin, A.L. Jayaraman, X. Zhang, F.C. Harwood, and P.J. Houghton. 2002. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.PG - 13907-17. J Biol Chem 277: 13907-13917.

219. Williams, B.R. 1999. PKR; a sentinel kinase for cellular stress. Oncogene 18: 6112-6120.

220. Takizawa, T., C. Tatematsu, and Y. Nakanishi. 2002. Double-stranded RNA-activated protein kinase interacts with apoptosis signal-regulating kinase 1. Implications for apoptosis signaling pathways. Eur J Biochem 269: 6126-6132.

221. Samuel, C.E., K.L. Kuhen, C.X. George, L.G. Ortega, R. Rende-Fournier, and H. Tanaka. 1997. The PKR protein kinase--an interferon-inducible regulator of cell growth and differentiation. Int J Hematol 65: 227-237.

222. Gerlitz, G., R. Jagus, and O. Elroy-Stein. 2002. Phosphorylation of initiation factor-2 alpha is required for activation of internal translation initiation during cell differentiation. Eur J Biochem 269: 2810-2819.

223. Munoz, F., M.E. Martin, J. Manso-Tomico, J. Berlanga, M. Salinas, and J.L. Fando. 2000. Ischemia-induced phosphorylation of initiation factor 2 in differentiated PC12 cells: role for initiation factor 2 phosphatase.PG - 2335-45. J Neurochem 75: 2335-2345.

224. Brockdorff, J., M. Nielsen, A. Svejgaard, P. Dobson, C. Ropke, C. Geisler, and N. Odum. 1997. Protein phosphatase 2A plays a critical role in interleukin-2-induced beta 2-integrin dependent homotypic adhesion in human CD4+ T cell lines.PG. Cytokine 9: 333-339.

225. Ben-Asouli, Y., Y. Banai, Y. Pel-Or, A. Shir, and R. Kaempfer. 2002. Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR.PG. Cell 108: 221-232.